Scarica l'app Stockscreener
130.68
2.57%
3.27
Dopo l'orario di chiusura:
130.68
Precedente Chiudi:
$127.41
Aprire:
$128.97
Volume 24 ore:
984.18K
Relative Volume:
1.05
Capitalizzazione di mercato:
$7.68B
Reddito:
$551.35M
Utile/perdita netta:
$-189.33M
Rapporto P/E:
-39.70
EPS:
-3.2916
Flusso di cassa netto:
$-35.09M
1 W Prestazione:
+5.17%
1M Prestazione:
-8.09%
6M Prestazione:
+15.43%
1 anno Prestazione:
+27.69%
Intervallo 1D:
$125.43
$131.73
Intervallo di 1 settimana:
$122.69
$132.24
Portata 52W:
$73.16
$148.11
Glaukos Corp Stock (GKOS) Company Profile
Nome
Glaukos Corp
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
130.68 | 7.68B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Buy |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corp Borsa (GKOS) Ultime notizie
Glaukos Corp (GKOS) Institutional Confidence - TradingKey
Glaukos Corp (GKOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Glaukos Corp (GKOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Glaukos CDO Navratil sells $200,855 in company stock - Investing.com
Glaukos (GKOS) development chief sells 1,537 shares under 10b5-1 plan - Stock Titan
Glaukos Corp (GKOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Glaukos Corp (GKOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Glaukos Corp (GKOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Glaukos Corp (GKOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GKOS Maintained by Needham -- Price Target Raised to $150 - GuruFocus
Needham raises Glaukos stock price target on corneal treatment outlook - Investing.com
Needham raises Glaukos stock price target on corneal treatment outlook By Investing.com - Investing.com Nigeria
Glaukos Corp (GKOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Glaukos (NYSE: GKOS) discloses insider sales and vesting in Form 144 - Stock Titan
GKOS Maintained by Citigroup -- Price Target Raised to $162 - GuruFocus
Clearbridge Investments LLC Lowers Stake in Glaukos Corporation $GKOS - MarketBeat
GKOS Reiterated by BTIG -- Price Target Maintained at $162 - GuruFocus
Stifel reiterates Glaukos stock rating on regulatory optimism By Investing.com - Investing.com South Africa
Stifel reiterates Glaukos stock rating on regulatory optimism - Investing.com
Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus - AD HOC NEWS
Why Is NYSE Composite Watching Glaukos’ iDose TR Adoption Momentum? - Kalkine Media
Midday Stock Roundup: Alignment Healthcare Surges - Orange County Business Journal
A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE), Dexcom (DXCM) and Glaukos (GKOS) - The Globe and Mail
Glaukos Corp Balance Sheet – XETR:6GJ - TradingView
Glaukos Corp Statistics – XETR:6GJ - TradingView
Glaukos Corp Cash Flow – XETR:6GJ - TradingView
Glaukos Corp Revenue Breakdown – XETR:6GJ - TradingView
Glaukos Corp stock (US3773221029): shares near recent highs as valuation comes into focus - AD HOC NEWS
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Yahoo Finance
Glaukos (NYSE: GKOS) investors approve board slate, pay and Ernst & Young - Stock Titan
Glaukos Corp. Hits Day High with Strong 7.43% Intraday Surge - Markets Mojo
Glaukos (GKOS) director Leana Wen granted RSUs and options in 2026 - Stock Titan
Glaukos (NYSE: GKOS) director granted new RSUs and stock options - Stock Titan
Glaukos (GKOS) director Denice Torres granted RSUs and stock options - Stock Titan
Glaukos (GKOS) director Mark Foley receives new RSUs and stock options - Stock Titan
GLAUKOS (GKOS) director David Hoffmeister receives new RSU and option grants - Stock Titan
Glaukos Corp (GKOS) director Kliman receives new RSU and option awards - Stock Titan
Director at Glaukos (NYSE: GKOS) granted new stock units and options - Stock Titan
EBITDA per share of Glaukos Corp – FWB:6GJ - TradingView
Glaukos Corp stock (US3773221029): shares active on NYSE as market watches next catalysts - AD HOC NEWS
Glaukos (GKOS) director exercises 15,000 options at $24.69 - Stock Titan
Goldman Sachs Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153 - Moomoo
Glaukos Corp. Stock Hits Day Low of $118.64 Amid Price Pressure - Markets Mojo
Glaukos (GKOS) Faces Selling Pressure Amid iDose Procedure Conce - GuruFocus
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
BTIG raises Glaukos stock price target to $162 on product pipeline - Investing.com
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Glaukos Corp Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):